Guselkumab for ulcerative colitis in Chinese patients
Part of Digestive system clinical trials.
This study tracks how well guselkumab (Tremfya) works in real-world Chinese patients with moderate to severe ulcerative colitis who haven't tried advanced therapies before. It helps doctors understand how the drug performs outside of controlled trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe ulcerative colitis (UC), meaning your symptoms are active enough to need advanced treatment.
- You have never taken advanced therapies like biologics or JAK inhibitors for your UC.
- Your doctor has decided to start you on guselkumab (Tremfya) as your first advanced treatment.
- You are not currently in a severe UC flare that needs immediate surgery or hospitalization.
- You have not had your colon removed or had pouch surgery.
- You are willing to sign a consent form allowing your medical data to be reviewed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well guselkumab (Tremfya) works for people with moderate to severe Crohn's disease or ulcerative colitis when used in everyday medical practice. It collects information from patients who are prescribed this medicine to better understand its long-term effects and safety.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This study looks at how well guselkumab (Tremfya), a treatment for Crohn's disease and ulcerative colitis, works in everyday patients. Researchers will review medical records to see how long people stay on the medicine and how it helps their symptoms.
This study looks at how well guselkumab (Tremfya) works for people with moderate-to-severe Crohn's disease or ulcerative colitis in everyday medical practice in Italy. If you qualify, you will receive the treatment normally prescribed by your doctor and help researchers track its real-world effectiveness.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
Hear when a new Colitis, Ulcerative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.